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Abstract
In December 2017, the National Academy of Neuropsychology convened an interorganizational Summit on Population 
Health Solutions for Assessing Cognitive Impairment in Geriatric Patients in Denver, Colorado. The Summit brought 
together representatives of a broad range of stakeholders invested in the care of older adults to focus on the topic of cogni-
tive health and aging. Summit participants specifically examined questions of who should be screened for cognitive impair-
ment and how they should be screened in medical settings. This is important in the context of an acute illness given that 
the presence of cognitive impairment can have significant implications for care and for the management of concomitant 
diseases as well as pose a major risk factor for dementia. Participants arrived at general principles to guide future screen-
ing approaches in medical populations and identified knowledge gaps to direct future research. Key learning points of the 
summit included:
• recognizing the importance of educating patients and healthcare providers about the value of assessing current and 
baseline cognition;
• emphasizing that any screening tool must be appropriately normalized and validated in the population in which it is 
used to obtain accurate information, including considerations of language, cultural factors, and education; and
• recognizing the great potential, with appropriate caveats, of electronic health records to augment cognitive screening 
and tracking of changes in cognitive health over time.
Keywords:  Elderly, Geriatrics, Aging, Mild cognitive impairment
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Introduction
The United States faces a dramatic demographic shift as 
its population ages, with important implications for health 
care delivery and costs (Miquel et al., 2017). Age is a sig-
nificant risk factor for many medical conditions, including 
cognitive impairment and dementia, and as the number of 
people over age 65 increases, the number of people living 
with these conditions will substantially increase (Prince, 
Comas-Herrera, Knapp, Guerchet, & Karagiannidou, 
2016). Cognitive impairment is of particular concern 
because it is a clinically dominant comorbidity influencing 
the presentation and management of concomitant condi-
tions. Furthermore, people with cognitive impairment have 
been shown to use health care services in general and specif-
ically emergency department (ED) services more frequently 
and at higher cost than those without cognitive deficits 
(LaMantia, Stump, Messina, Miller, & Callahan, 2016) and 
they utilize more outpatient visits compared to those with-
out cognitive impairment (Chung et al., 2014; St-Hilaire, 
Hudon, Preville, & Potvin, 2017). These individuals also 
experience complications of co-existing medical condi-
tions and have caregivers who experience substantial bur-
den (Bradford, Kunik, Schulz, Williams, & Singh, 2009). 
Cognitive impairment, which can be indicative of an acute 
condition, is often a precursor of dementia, a longer term 
condition involving the development of impaired cognitive 
function in multiple domains which has an impact on the 
individual’s daily life. Focusing on the broad condition of 
cognitive impairment as well as dementia and Alzheimer’s 
disease is important given that many causes of cognitive 
impairment are reversible if identified early.
The expected increase in the number of people with 
sustained cognitive impairment and dementia portends a 
substantial economic impact. Attempts to aggregate all asso-
ciated elements of care to summarize the total costs of cog-
nitive impairment to individuals, families, and the nation 
as a whole is complicated due to diverse data sources and 
differing measurement methodologies, among other fac-
tors. One of the most convincing estimates however can be 
generated for dementia care which results in the additional 
annual costs to the individual between $41,700 and $45,800 
(adjusted for inflation in 2016 dollars) for informal care 
and care purchased in the marketplace (Hurd, Martorell, 
Delavande, Mullen, & Langa, 2013). Of that amount, the 
cost to individuals for their share of nursing home care 
totaled $15,300 and personal care in the home amounted to 
$6,800. Moreover, at over $119.6 billion for a national total 
of dementia-related direct health expenditures, the costs of 
dementia are similar to and in some cases exceed expendi-
tures for heart disease and are substantially larger than the 
costs of cancer (Hurd et  al., 2013). This is a conservative 
estimate given that dementia is present in a more restricted 
population than those people who experience significant 
cognitive deficits and come for treatment to the Emergency 
Department and Primary Care office. Because of this sub-
stantial economic impact, detecting and acting on cognitive 
compromise early is an economic imperative as well as a clin-
ical necessity (Robinson, Tang, & Taylor, 2015) to improve 
the lives and care of people who live with dementia and 
their care providers (Barnett, Lewis, Blackwell, & Taylor, 
2014). Furthermore, the presence of cognitive impairment 
has the potential to influence the effectiveness of doctor–
patient communication, treatment adherence, the likelihood 
of medical follow-up, selection of appropriate medications, 
and likely medication side effects, thereby impacting overall 
health, which may add to caregiver burden and health costs.
Cognition should, therefore, be considered an important 
modifier of clinical outcomes and play an important role 
in clinical assessment (Weintraub et  al., 2014). Screening 
for cognitive impairment may uncover underlying remedi-
able conditions, or alert healthcare providers to increase 
surveillance for signs of progressive dementia. Identifying 
cognitive deficits and a dementing disease earlier allows for 
a more timely intervention, referrals to home and commu-
nity-based services and social supports, and safeguarding 
health and financial management. The primary care setting 
is well positioned to provide early recognition of cogni-
tive impairment and dementia; however, early symptoms 
of dementia, such as memory impairment, are not always 
apparent during a routine office visit and may not be voiced 
by the patient as a complaint. As a result, cognitive impair-
ment and even frank dementia are often undiagnosed in 
primary care (Valcour, Masaki, Curb, & Blanchette, 2000; 
Boustani et  al., 2005; Borson, Scanlan, Watanabe, Tu, & 
Lessig, 2006; Bradford et al. 2009). For example, a 2011 
survey across 21 states found that 12.7% of adults over 
age 60 reported worsening memory problems in the prior 
12 months, 35.2% of whom acknowledged accompanying 
functional difficulties, but only 32.6% of these individuals 
had discussed their concerns with a health care professional 
(CDC, 2013). Consequently, waiting for an expressed com-
plaint may delay expeditious investigation of underlying 
causes of impairment and addressing individual needs. 
Cognitive screening and diagnosis in the ED and primary 
care settings could be beneficial to improve early detec-
tion and intervention and to initiate referrals to commu-
nity-based care and assistance with treatment planning. In 
addition, identifying the presence of underlying cognitive 
impairment in older Emergency Department patients will 
have an impact on processes of care for them in the ED 
and impact clinical outcomes since dementia is the main 
risk factor for delirium and other atypical presentations 
of acute disease. Cognitive screening should not be lim-
ited to primary care and the ED as other specialty service 
clinics may also choose to implement cognitive screening 
protocols. For example, it is noteworthy that the American 
Diabetes Association recently recommended screening for 
early detection of mild cognitive impairment or dementia 
for adults 65 years of age or older at the initial clinic visit 
and annually as appropriate, recognizing the impact that 
cognitive impairment can have on diabetes management, 
comorbidities, and activities of daily living (ADA, 2018)
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Although it has been widely recognized that the use of 
cognitive assessment tools increases the detection of cog-
nitive impairment, which leads to early intervention, it 
is unclear how best to screen for cognitive impairment, 
including who should be screened, what tools should be 
used, who would carry out screening, and what sequence of 
procedures would follow screening (Cordell et al., 2013). 
Furthermore, it needs to be determined if a case-finding 
approach (i.e., using decision support tools to detect “at-
risk” individuals) should be employed versus a mass popu-
lation screening approach to detect early cognitive changes 
(Moyer & U.S. Preventive Services Task Force, 2014).
To examine how an interdisciplinary approach can 
best support the cognitive health of older Americans, the 
National Academy of Neuropsychology sponsored a 
Geriatric Summit on Assessing Cognitive Disorders Among 
the Aging Population on the 7th and 8th of December, 2017, 
in Denver, Colorado. The summit included an expert panel 
of speakers and participants representing the fields of neur-
ology, neuropsychology, gerontology, geropsychiatry, pri-
mary care, emergency medicine, psychology, collaborative 
care, social work, and nursing, disease advocacy and policy 
groups, governmental agencies and providers, neuropsycho-
logical test publishers, and insurance providers. Participants 
came together to discuss the importance of cognitive screen-
ing and how best to implement screening in the assessment 
of older adults coming to the primary care and emergency 
room setting for medical care. This document summarizes 
the proceedings and content of the Summit and highlights 
the recommendations and key takeaways regarding unmet 
needs and future directions arrived at by the participants.
Demographics of the Aging Population of the 
United States
The population of the United States is aging. While 9% 
of the population was over 65 years of age in 1960, that 
proportion is now 15% and will approach 25% by 2060 
(Mather, Jacobson, & Pollard, 2015). The number of peo-
ple over age 65 was approximately 49 million in 2016 and 
is projected to be 98 million by 2060 (Mather et al., 2015). 
During that same period, the number of people 85 years 
of age and older is expected to more than triple (Ortman, 
Velkoff, & Hogan, 2014; Mather et al., 2015).
The older population is also becoming more diverse 
with respect to race and ethnicity (Ortman et  al. 2014). 
Nationally, all race and ethnic groups increased between 
2015 and 2016 with the largest increase among the Asian 
and those self-identified as multi-race groups (U.S. Census 
Bureau, 2017). In 2014, the great majority (more than 
75%) of those over 65  years of age were non-Hispanic 
white (Mather et al., 2015). The percent of people over age 
65 who are Hispanic is expected to increase to 22% by 
2060 (Mather et al., 2015). The increase in cultural, racial, 
and language diversity has important implications for the 
delivery of care to older adults since care is improved when 
language concordance exists between individuals and their 
healthcare care providers (Fernandez et  al., 2011; Tang, 
Lanza, Rodriguez, & Chang, 2011; Jih, Vittinghoff, & 
Fernandez, 2015; Meuter, Gallois, Segalowitz, Ryder, & 
Hocking, 2015; Parker et al., 2017).
The regional and housing settings of older adults also 
have implications for health care delivery. The population 
over age 65 is not evenly distributed, tending to be located 
in certain parts of the country and to reach a higher pro-
portion of the population in rural counties (Mather et al., 
2015). Only about 4% of this population live in institutional 
settings such as nursing homes and a substantial propor-
tion, as many as 56% of women and 30% of men over age 
85, live alone in a personal home (Mather et al., 2015) and 
79.5% of householders age 65 and older owned their own 
homes as of 2016 (U.S. Cenus Bureau, 2018). For people liv-
ing in rural areas, and as the number of older people living 
alone increases, there may be an associated increase in the 
demand for services such as personal care and other home 
and community-based services (Mather et al., 2015) and for 
technologies that allow people to receive some care remotely.
Importance of Cognition to Successful Aging
Maintaining cognitive health is important to successful 
aging. Age is the strongest risk factor for cognitive impair-
ment (Blazer, Yaffe, & Liverman, 2015; Moyer & Force, 
2014). Cognition is multifactorial and encompasses mem-
ory, attention, language, visuospatial skills, and executive 
functioning (Moyer & Force, 2014). Cross-sectional stud-
ies indicate that some aspects of cognitive ability (specifi-
cally, measures of fluid ability and processing speed) appear 
to steadily decline with age across all individuals, starting 
at around 30 years of age (Miquel et al., 2017). Usually, 
this decline does not affect everyday function, perhaps 
because people are able to maintain functional competence 
using cognitive abilities such as concrete knowledge that do 
not decline or even improve with increasing age (Salthouse, 
2012). There are, however, numerous “normal” age-related 
changes in cognition that do affect the everyday function of 
older adults and place them at increased risk for functional 
and safety-related difficulties. While there is vast hetero-
geneity in the cognitive abilities of older adults, signifi-
cant cognitive decline can contribute to errors in financial 
decision-making, impaired driving, and performance on 
technology-based tasks (Blazer et al. 2015). Avoiding risk 
factors for cognitive impairment and dementing diseases 
should be prominent goals for healthcare.
The ability to recognize cognitive impairment is import-
ant for many reasons. Some underlying causes of cognitive 
impairment, such as medication side effects or metabolic 
disorders, are potentially reversible. Early recognition 
of these conditions can lead to effective treatment and 
improved quality of life for both the person and their fam-
ily. Cognitive impairment can affect adherence to treatment 
and lead to misuse of medications, which can lead to poor 
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physical and emotional health outcomes (Stilley, Bender, 
Dunbar-Jacob, Sereika, & Ryan, 2010). Consequently, 
detection of cognitive impairment would allow healthcare 
professionals to modify their care pathways and provide 
education to improve treatment adherence (Arlt, Lindner 
Rösler, & von Renteln-Kruse, 2008).
Additionally, specific recognition of mild cognitive 
impairment syndrome (MCI) is important because it is 
a risk factor for progressive dementia, increasing its risk 
10-fold (Belleville et al., 2017). Awareness of mild cogni-
tive impairment can improve surveillance for and detection 
of Alzheimer’s disease or other dementing diseases, and 
allow people access to clinical trials and to better plan for 
the future, along with their families and caregivers (Sach-
Ericsson & Blazer, 2015).
Sustained cognitive impairment and dementia are the 
main contributors to institutionalization in the older adult 
(Luppa et al., 2008) and represent substantial health care 
costs (The Healthy Brain Initiative: The Public Health 
Road Map for State and National Partnerships, 2013–
2018, 2013). Given that healthcare resources are limited, 
informed decision making on health care management and 
efficient allocation of resources are important to minimize 
loss of opportunities (Handels, Wolfs, Aalten, Verhey, & 
Severens, 2013). For example, there is considerable research 
on redesigning systems of care intended to promote more 
efficient, but equally effective, allocation of treatment 
resources (Callahan et al., 2014; French et al., 2014; Long, 
Moriarty, Mittelman, & Foldes, 2014). These models com-
monly emphasize linkages with community resources and 
multi-agency coordination including health care providers, 
dementia care managers, internet-based care management 
protocols, and collaborative care planning with caregiv-
ers. Dementia is not the only area in which the force of 
economic reasoning has been introduced. The cost of dis-
ease, benefits of testing and intervention, as well as cost-
effectiveness and cost–benefit of psychological assessment, 
were introduced and discussed at length by Yates and 
Taub (2003); Neumann (2004); Neumann and Greenberg 
(2009); and Neumann and Weinstein (2010).
How to Detect Cognitive Impairment
The importance of identifying cognitive impairment is 
underscored by the inclusion, beginning in 2011, of assess-
ment of cognitive function as part of the Medicare Annual 
Wellness Visit (AWV) benefit, as authorized by the Patient 
Protection and Affordable Care Act of 2010 (“Federal 
Register, Part II: Department of Health and Human 
Services, Center for Medicare & Medicaid Services,” 2010). 
Medicare is statutorily prohibited from paying for routine 
physical checkups with certain exceptions, the “Welcome to 
Medicare” exam, and the “Annual Wellness Visit” (AWV), 
which became available in 2011. The AWV includes and/
or takes into account a health risk assessment and creates 
a personalized prevention plan that includes establishment 
of, or update to, the individual’s medical and family history, 
a list of the individual’s current providers and suppliers and 
medications prescribed; measurement of height, weight, 
body-mass index or waist circumference, and blood pres-
sure; detection of any cognitive impairment; establishment 
or update of an appropriate screening schedule for the next 
5–10 years; establishment or update of a list of risk factors 
and conditions (including any mental health conditions) for 
which interventions are recommended or underway; and 
furnishing of personalized health advice and referral, as 
appropriate, to health education or preventive counseling 
services or programs. The regulation implementing AWV 
states that in order to detect individuals at risk for cog-
nitive impairment, the health professional should use dir-
ect observation in combination with information reported 
by the patient and/or concerns expressed by family and 
friends. In regard to cognitive screening, the U.S. Preventive 
Services Task Force (USPSTF) has noted that evidence to 
date is not sufficient enough to support screening of asymp-
tomatic populations, nor is evidence sufficient to require 
the use of a specific tool. While no nationally recognized 
screening tool for detection of cognitive impairments exists 
at the present time, continuing efforts to identify a stand-
ardized screening methodology is needed. Still, relying 
simply on interview to detect cognitive impairment is insuf-
ficient given that cognitive deficits may go undetected by 
health care professionals using interview alone (Chodosh 
et al., 2004).
In 2013, the Alzheimer’s Association published recom-
mendations for implementing the detection of cognitive 
impairment during the AWV through the use of objec-
tive cognitive measures rather than solely through voiced 
complaint or clinical impression (Cordell et  al., 2013). 
The recommendations include an algorithm that begins 
with assessing every patient for signs or symptoms of cog-
nitive impairment via medical records, observations, and 
concerns expressed by the patient or other informant. 
Administration of a cognition assessment tool would fol-
low unless both the patient and a knowledgeable informant 
was present that affirmed cognition was normal (Cordell 
et al., 2013). If no knowledgeable informant is available at 
the visit, a brief validated cognitive assessment tool should 
always be used. Several brief (<5min) validated cognition 
assessment tools are recommended as options since no sin-
gle tool has been identified as best for this purpose (Cordell 
et al., 2013). If resulting scores indicate concerns of cogni-
tive impairment, the patient is referred for a full dementia 
evaluation (Cordell et al., 2013).
As mentioned above, in 2014, the USPSTF reviewed the 
evidence regarding screening the general population older 
than 65 years of age for cognitive impairment (Moyer & 
Force, 2014). The USPSTF arrived at an “I” rating (i.e., 
insufficient to assess the balance of benefits and harms 
of the service) regarding screening, concluding that there 
was insufficient evidence to weigh the benefits and harms 
of screening. Thus, routine screening of asymptomatic 
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individuals may not be a common practice at present. The 
Veterans Administration has released a fact sheet for clini-
cians recommending against general screening and recom-
mended the use of “dementia warning signs” consistent with 
the recommendations of the National Institute on Aging 
to identify patients who should be assessed for dementia 
(Clinician Fact Sheet: Detection of Dementia, 2011).
In 2015, The Gerontological Society of America (GSA) 
Workgroup on Cognitive Impairment Detection and 
Earlier Diagnosis published a report and recommendations 
to improve the assessment of older adults for cognitive 
impairment during visits with their primary care provid-
ers (The Gerontological Society of America Workgroup on 
Cognitive Impairment and Earlier Diagnosis: Report and 
Recommendations, 2015). The purpose of the GSA report 
was to achieve earlier diagnosis of Alzheimer’s disease and 
related dementias through increasing detection of cog-
nitive impairment. The GSA recommendations include a 
process for approaching the AWV, summarized as KAER: 
Kickstart the conversation, Assess for cognitive impair-
ment, Evaluate for dementia with full diagnostic workup if 
cognitive impairment is detected, and Refer to community 
resources and clinical trials or other research, if appropri-
ate. The GSA recommended the routine use of one of the 
structured cognitive instruments recommended in the 2013 
Alzheimer’s Association Report. Unlike the Alzheimer’s 
Association algorithm, it recommended a structured cog-
nitive instrument in all situations, even if a knowledgeable 
informant confirmed a patient’s report that cognitive prob-
lems were not present.
The Summit: Summary of Issues Addressed
Seven presentations introduced important aspects of multi-
disciplinary topics including how and by whom cognition 
is assessed, how assessment fits into current health care and 
reimbursement models, how electronic medical and health 
records can facilitate assessment, and how assessment might 
differ depending on setting such as emergency versus primary 
care. These presentations served as a basis for discussion after 
each talk and during the breakout groups that followed.
Opportunities for Improving Cognitive 
Assessment in Older Adults
A substantial amount of research has been devoted to 
the diagnosis of and screening for Alzheimer’s disease, a 
form of progressive neurological disease causing demen-
tia. In 1984, the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s 
Disease and Related Disorders Association (NINCDS-
ADRDA) Work Group published criteria to refine the clin-
ical diagnosis of Alzheimer’s disease, noting that improved 
diagnosis was required for therapeutic trials; at least 20% 
of people diagnosed with Alzheimer’s were found not to 
have the disease upon autopsy (McKhann et al., 1984). The 
workgroup noted that no specific validated laboratory tests 
existed for Alzheimer’s disease. Over 30  years later, this 
remains true today, though NIA-AA is moving towards a 
biological definition of Alzheimer’s disease (Jack, Bennett, 
& Blennow, 2018) with the availability of CSF markers and 
pathologically validated brain imaging methods to detect 
with a high degree of certainty the presence or absence of 
amyloid plaque pathology in the brain with using FDA-
approved radiopharmaceuticals (Clark, Schneider, & 
Bedell, 2011; Jack, Albert, & Knopman, 2011; Jack et al., 
2013; Varma et  al., 2018). Therefore, incorporating CSF 
and brain imaging biomarkers may be useful in the future.
Screening for cognitive impairment is quite different 
than screening for other medical conditions where a positive 
result may be diagnostic of a true condition (e.g., a colon-
oscopy for colon cancer). In the case of cognitive screen-
ing the Summit participants raised the concern that some 
may equate a positive screen with a diagnosis of demen-
tia. Ashford and colleagues (2006) explain that in regards 
to cognitive impairment “screening tests determine when 
diagnostic tests should be considered” (p. 78). Detecting the 
presence of symptoms or signs of a disease does not require 
that formal diagnostic criteria be met. Consequently a posi-
tive screen should “only lead [s] to a recommendation of 
a second step in assessment” (p.  78) which may include 
imaging, neuropsychological testing, and activities of daily 
living assessments. Furthermore, there are many etiolo-
gies of cognitive impairment and dementia and differen-
tial diagnosis may require different evaluation methods. 
The distinction between tools for cognitive screening and 
diagnosis of dementia was a theme returned to frequently 
during the summit. Some important differences between 
screening (e.g., brief assessment tools in the clinical setting) 
and diagnostic tools (e.g., neuropsychological testing, PET 
scan, etc.) for evaluating cognitive decline and dementia are 
summarized in Table 1.
Factors Influencing Diagnosis
It is well established that people with cognitive impairment 
and frank dementia often go undetected and are not prop-
erly evaluated to arrive at a diagnosis. The substantial rate 
of under-diagnosis may be due in part to the attitudes of 
some primary care physicians, who may be disinclined to 
diagnose something for which they feel there is a lack of 
useful interventions, as well as to discomfort on the part of 
healthcare providers and patients around the idea of demen-
tia (Ofri, 2014). Additionally, most providers do not receive 
explicit training in how to identify cognitive impairment 
versus a diagnosis of dementia. However there are train-
ing programs available to help health care professionals 
identify some of the clinical differences between the major 
dementias (see: https://www.alz.org/health-care-profession-
als/dementia-diagnosis-diagnostic-tests.asp). Still, both the 
steps necessary to arrive at a dementia diagnosis and the 
disclosure of this diagnosis to a patient and their family can 
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be time consuming and may require referrals for commu-
nity resources. Patient and family/caregiver reluctance can 
also contribute to under-diagnosis; many people who are 
referred for further diagnostic tests do not follow up and 
many people would prefer not to know about a diagnosis 
for a condition with no available clinical treatment (Beck, 
2012). Some feel an early diagnosis is “cruel” because, with-
out a more effective treatment, the benefits do not outweigh 
the harms (Beck, 2012; Maguire et al., 1996), with potential 
harms to include a fear of loss of independence or of becom-
ing a burden to family and friends. However, it should be 
noted that other services and supports, including home and 
community-based services, are available that may be benefi-
cial to individuals with dementia and their caregivers.
In contrast, the World Alzheimer Report states that most 
people would wish to know about an Alzheimer’s diagnosis 
and that earlier diagnosis can improve the care and support 
of patients with Alzheimer’s disease (Prince et  al., 2016). 
A survey of over 1,400 people found that most would take 
a test to predict a future disease, including Alzheimer’s 
disease, even if the test were not perfect and even in the 
absence of more effective treatments (Neumann et  al., 
2012). Many people with Alzheimer’s disease report they 
wish they had received an earlier diagnosis, before unrec-
ognized dementia led to difficulties such as mismanagement 
of finances (Kolata, 2010).
Early recognition of cognitive impairment may have 
benefits in addition to identification of people who are at 
higher risk and should be monitored for Alzheimer’s dis-
ease. Cognitive impairment can increase the risk of cogni-
tive side effects of medication and as a predisposing factor 
increases the risk of a delirium with acute illness, medica-
tion side effects, or procedures. Some medications may be 
contraindicated depending on the etiology of the dementia. 
In addition, cognitive impairment interferes with treatment 
adherence and increases patient frustration. Awareness of 
the presence cognitive impairment allows healthcare pro-
viders to better watch for these effects and to change care 
plans accordingly. Appropriate management of chronic dis-
eases that require self-management, such as diabetes, also 
can be adversely affected if cognitive impairment is unrec-
ognized or unaddressed (Sinclair, Girling, & Bayer, 2000). 
Modification of treatment and engaging family members 
and caregivers to assist in supervising medications and care 
can be critical to reducing medication errors and prevent-
able hospitalizations.
Who Should be Screened for Cognitive 
Impairment?
Although cognitive assessment is a benefit of the Medicare 
Annual Wellness Visit (AWV), the question of who should 
be screened outside of that forum and how they should 
be screened remains controversial. As stated earlier, the 
USPSTF reviewed the available science and concluded there 
was insufficient information to enable them to assess the 
relative benefits and harms of screening the general popu-
lation of persons over 65 years of age for cognitive impair-
ment (Moyer & Force, 2014). Therefore, the USPSTF made 
no recommendation regarding screening and noted that 
potential benefits of detection and early intervention have 
small effects or a lack of published evidence. Some poten-
tial adverse side effects associated with screening and cur-
rent treatments were also noted (Moyer & Force, 2014). 
The Alzheimer’s Association has published recommenda-
tions for implementing the cognitive assessment benefit of 
the AWV, including the recommendation that standard-
ized tools be used to make assessments because relying 
on clinical judgment is insufficient (Cordell et  al., 2013). 
To help identify who should be screened during an AWV 
when there is no patient complaint and a knowledgeable 
informant is not present, a Dementia Screening Algorithm 
tool based upon dementia risk has been developed as an 
alternative to the Alzheimer’s Association recommended 
algorithm (Barnes et al., 2014), although this algorithm has 
not been prospectively evaluated.
The USPSTF report stated that, because evidence for 
the long-term benefits of available treatments on cogni-
tive outcomes is not available, research into the effects of 
screening and early detection of mild to moderate dementia 
Table 1. Differences between screening and diagnostic tools
Cognitive screening measures Diagnostic tests for dementia
Purpose of test Detect potential disease indicators Establish presence or absence of a specific disease
Target population Large number of individuals selected on the basis of 
demographic or clinical characteristics who are not 
previously diagnosed with the condition of interest
Symptomatic individuals, or those at high risk
Test characteristics • Simple, acceptable to patients and staff
•  Inexpensive; the benefit must justify the cost of 
screening large numbers of individuals
•  May be invasive; precision of test weighted more 
than its patient acceptability
•  May be expensive; cost is justified as necessary to 
establish diagnosis
Positive result threshold Set to achieve high sensitivity (maximize potential 
positives)
Set to achieve high specificity (minimize false negatives)
Implication of positive 
result
Suspicion of disease; in combination with other risk 
factors provides reason for additional follow up
Provides definite diagnosis and thus prognosis and 
identification of appropriate management
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on decision making and planning could provide support 
for general population screening of individuals over age 
65 (Moyer & Force, 2014). A single-blinded, randomized, 
controlled trial has been initiated to fill this knowledge 
gap identified by the USPSTF (Fowler et  al., 2014). This 
trial randomly assigned individuals to be screened for cog-
nitive impairment as compared to usual care, with those 
who screen positive referred for follow-up. Fowler and 
colleagues (2015) reported on an initial study of phys-
ician behaviors when physician groups were randomized 
to receive information about a patient’s cognitive function 
based on results of neuropsychological testing compared 
to physician groups with treatment as usual. Although the 
response was modest, physicians that received information 
about cognitive functioning were more likely to order blood 
tests to rule out reversible cognitive impairment and to 
document discussions about cognition with their patients. 
Patients from this group were also more likely to be on 
a cognitive-enhancing medication at follow-up. Rates of 
progression to dementia and cognitive outcomes were not 
different across groups; however, authors note that longer 
term benefits of this nature may not be identifiable with the 
relatively short study follow-up of 2 years compared with 
the long prodromal phase of Alzheimer’s disease. Results 
of this initial study can be extrapolated to show potential 
benefits of cognitive screening in a primary care setting.
The American Academy of Neurology has recognized 
the important role of the Medicare Annual Wellness Visit 
in detecting mild cognitive impairment. In its 2018 practice 
guideline “Update: Mild Cognitive Impairment” it recom-
mends that when performing a Medicare Annual Wellness 
Visit, clinicians should not rely on historical report of sub-
jective memory concerns alone when assessing for cogni-
tive impairment and a brief, validated cognitive assessment 
instrument should be used (no specific instruments were 
recommended). The guidelines further recommend a for-
mal clinical assessment and medical evaluation to identify 
and treat MCI risk factors that are potentially modifiable 
(Petersen, Lopez, & Armstrong, 2018).
Improvements in assessment technology could also assist 
in collecting the needed information. For example, research-
ers at Washington University in St. Louis, in collaboration 
with the Dominantly Inherited Alzheimer Network-Trials 
Unit, have created an Ambulatory Research in Cognition 
(ARC) smartphone app to increase precision and reliability 
of cognitive assessment to help in clinical trials. The app tests 
multiple aspects of cognition in short bursts multiple times 
per day; averaging the test results over time can avoid placing 
too much weight on a single assessment that may be influ-
enced by variables such as time of day. The test was designed 
to minimize cultural and linguistic bias. Initial results indicate 
the app is feasible, reliable, and well tolerated (Hassenstab 
et al., 2017). However, this was in a younger population, so it 
remains to be seen how feasible this will be for older adults.
Summit participants discussed the importance of com-
bating some physicians’ feelings of helplessness about 
assessing cognitive impairment and dementia and the need 
to provide information about benefits of early detection as 
well as solutions for patients who screen positive and their 
families and caregivers, as appropriate. They noted that the 
calculus of screening risks and benefits changes entirely if 
effective interventions for dementia are identified. Given 
the lack of solutions however, they emphasized the import-
ant need for the clinician to initiate conversations about 
brain health with the patient and their caregivers, and to 
provide referrals for additional education and supportive 
community services.
Participants also noted the importance of broadening 
the discussion to include all cognitive impairment rather 
than strictly focusing on Alzheimer’s disease. Though there 
may not be effective interventions for Alzheimer’s disease, 
many causes of cognitive impairment are reversible and 
patients can see substantial benefit if the source of cognitive 
impairment is identified early. An important aspect of early 
recognition of cognitive impairment is using tools validated 
with respect to language and cultural factors.
Opportunities and Challenges of Assessing 
Cognition amidst Evolving Systems
The Centers for Medicare & Medicaid Services (CMS) is 
the largest purchaser of healthcare in the world, covering 
one-third of Americans through Medicare, Medicaid, and 
the Children’s Health Insurance Program. Like the pri-
vate sector, health care service payments through CMS is 
moving from a fee-for-service model towards models that 
pay based on value rather than volume. These new models 
are person-centered and outcomes-based, with incentives 
for improved outcomes (such as reduced rates of hospital 
readmission) rather than volume and aim to support coor-
dinated rather than fragmented care. In these new models, 
a single payment may be based on an episode of care rather 
than multiple payments being made for every visit and test 
that comprise an episode. Accountable Care Organizations 
(ACOs) and other integrated care models provide well-
coordinated health care services with payment that is 
adjusted up or down based on domains including quality 
performance and reductions in the cost of care for the ben-
eficiaries for whom ACO clinicians are accountable.
A goal of CMS is to empower patients and providers to 
make healthcare decisions. For coverage purposes, a diag-
nostic test is coverable if there is sufficient evidence that the 
results from that test is useful in medical decision-making, 
and that the management ideally leads to clinically mean-
ingful, improved outcomes. Although no one test is univer-
sally accepted as the best test to detect cognitive impairment, 
several tests have been identified by the Gerontological 
Society of America (GSA) as satisfying criteria including 
being relatively fast to administer and having been recently 
validated in the United States (The Gerontological Society 
of America Workgroup on Cognitive Impairment and 
Earlier Diagnosis: Report and Recommendations, 2015). 
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As described earlier, the GSA provides a toolkit with infor-
mation, instruments, and materials including videos to sup-
port PCPs in implementing the KAER (Kickstart, Access, 
Evaluate and Refer) model. An important aspect of the 
KAER model is information to support communication 
about cognitive impairment and dementia, including the 
fact that conditions such as depression that often accom-
pany dementia can be managed.
There are several payment vehicles for the assessment 
of cognitive impairment within the 2017 physician fee 
schedule. New codes describe integrated behavioral health 
models including the psychiatric collaborative care model 
that involves coordination between the PCP and a psychi-
atric consultant, behavioral health specialist, or behavioral 
health care manager. A new code, G0505, was introduced in 
2017 specifically to pay for the assessment of patients with 
cognitive impairment, including dementia, and the creation 
of a care plan. Beginning in 2018 the G0505 code has been 
superseded with CPT code 99483 “Cognitive Assessment 
and Care Plan Services”. A requirement of this code is func-
tional assessment and use of standardized instruments for 
staging of dementia that incorporates most of the appropri-
ate features of a cognitive evaluation to arrive at a specific 
diagnosis. Importantly, this also sets the expectation that the 
caregiver is assessed for burden. Within the CMS Quality 
Payment Program (https://qpp.cms.gov), clinicians can be 
rewarded either through a merit-based incentive system, 
that includes quality measures specific to dementia care, or 
through participation in an advanced alternative payment 
model. These alternative payment models may serve benefi-
ciaries with dementia and caregivers well over time.
In October 2017, the US Department of Health and Human 
Services sponsored a Research Summit on Dementia Care in 
which care models for people with a diagnosis of or at risk 
for dementia were presented. Common elements of many care 
models included enhanced care coordination, enhanced access 
to care, referrals and access to home-and community-based 
services, and caregiver services and support. A key takeaway 
is that a cognitive impairment care episode does not end with 
screening, but must include all follow-up services, and define 
next steps and who is involved in those steps.
The Improving Medicare Post-Acute Care Transformation 
(IMPACT) Act standardizes data across post-acute care set-
tings such as long-term care hospitals and skilled nursing 
facilities to facilitate coordinated care and improve out-
comes. The data that should be collected to best manage 
cognitive impairment have yet to be determined.
Summit participants discussed challenges associated 
with current means of compensation and payment codes. 
One issue that presents significant limitations is that 
Psychologists (including neuropsychologists, geropsycholo-
gists, rehabilitation psychologists, etc.) are not included in 
the definition of care providers for this service and so are 
unable to bill using the G0505/ 99483 code for assessment 
services on which they are the experts. Within the new out-
comes-based billing models such as bundled services, such 
professionals may not be able to bill within a health system 
or practice group; thus, their expertise in assessing for cogni-
tive impairment may be excluded due to lack of reimburse-
ment mechanisms. Psychologists, particularly specialists 
within the psychology discipline, have critical skills and 
scientific knowledge that improve the cognitive screening 
procedure. They can have a key role in advising healthcare 
facilities about which screening measures are appropriate, 
how and where to set cutoff scores, teaching standardized 
administration of screening measures, and creating follow 
up trajectories for individual healthcare systems including 
EDs and primary care facilities. The proportion of alter-
native models employing team members who cannot bill 
Medicare directly is not known. In addition, it is not clear 
how to compensate for the increased cost associated with 
linguistic complexity when assessing and caring for a bene-
ficiary with limited English proficiency.
Predicting the Future with Clinical and Financial 
Data: Lessons Learned
Dr. Nirav Vakharia presented data from the Cleveland Clinic 
using an innovative approach to improve primary care, which 
may be relevant to screening for cognitive impairment. The 
Cleveland Clinic defines the population for whose care it is 
responsible to include the entire community, both those who 
seek medical care and those who do not. As an ACO, the 
Cleveland Clinic has been successful at reducing hospital read-
missions and reducing costs through coordinating care for 
high-risk patients, including the use of intensive home care.
To find high-risk patients, Cleveland Clinic has focused 
on identifying and targeting conditions that lead to high, 
unplanned utilization (as opposed to conditions which are 
known to be associated with high utilization such as can-
cer). Clinical judgment was found to be inferior to a holistic 
model that included behavioral, functional, and social factors 
in addition to medical data. In this model, cognitive impair-
ment, a behavioral factor, was the number one predictor of 
network leakage. Delirium was identified as a major factor 
that will likely predict risk of 30-day hospital readmission. In 
conclusion, financial, social, behavioral, and functional data 
can be integrated with clinical data to create risk models to 
identify patients who require increased coordination of care.
Summit participants discussed lessons that can be 
learned from the Cleveland Clinic experience regarding 
encouraging Primary Care Physicians and health systems 
to conduct a cognitive assessment even if it takes time from 
a limited appointment. To support this effort the Summit 
participants discussed the importance of demonstrating 
the benefit of screening by widely publicizing the data and 
its relevance; a strategy that has proven successful in the 
campaign to assess depression. Another consideration that 
was widely discussed is making screening easier or more 
efficient by allowing for medical assistants to conduct the 
screen and integrating the results directly into the elec-
tronic medical record. For example, in the Cleveland Clinic 
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system, if a delirium screen is positive, the medical record 
will prompt the clinician to consider adding delirium to the 
problem list.
Assessing Cognitive Impairment in the 
Emergency Department
The Geriatric ED Collaborative (Funded by the John 
A. Hartford Foundation and the West Health Foundation) is 
an interdisciplinary group including clinicians, social work-
ers, and nurses whose goal is to implement guidelines for the 
care of older patients in emergency departments across the 
United States. In 2013, geriatric emergency department guide-
lines were approved and published by the American College 
of Emergency Physicians, the American Geriatrics Society 
(AGS), the Emergency Nurses Association, and the Society for 
Academic Emergency Medicine (Geriatric emergency depart-
ment guidelines, 2014). These guidelines recommend routine 
cognitive screening of older ED patients for both chronic and 
acute cognitive impairment, (i.e. dementia and delirium) in 
those specialized emergency departments that have additional 
resources and established systems of referral.
Screening the ED population is quite different from 
screening the general population. In the general population, 
screening identifies mostly asymptomatic individuals who 
are at risk of a condition, while in the ED, the screening 
may more accurately be called case-finding with the pur-
pose of identifying a condition among a pre-selected popu-
lation of patients. Also, the time available for screening in 
the ED by a physician or other member of the interdisci-
plinary team is limited. Screening tools must be of the type 
that can be administered by other trained healthcare staff 
and must address the practical limitations of the environ-
ment such as assessing a patient who is lying on a gurney, is 
unable to sit up, unable to write, or even unable to vocally 
respond (Schnitker et al., 2015).
Implementation of cognitive screening in the ED faces 
many barriers. Routine universal cognition screening, in 
the ED may be challenging, even in individuals over the age 
of 65, due to environmental distractions, time and space 
constraints inadequate awareness and training of clinicians 
in recognizing cognitive impairment. Consequently, under 
ideal circumstances, routine cognition screening should 
be performed in a primary care or other professional out-
patient setting. The suspicion of cognitive impairment or 
dementia should however be included in the patient’s med-
ical record, so subsequent providers may be aware of the 
concerns of cognitive impairment and include that in their 
treatment planning. Identification of the patient’s primary 
physician, and effective communication between clinicians 
in the off-hours can, at times, be difficult. However, identifi-
cation of cognitive impairment in the ED may improve sub-
sequent care by improving patient adherence and follow-up 
thereby reducing reoccurring ED visits.
Finally, in the ED delirium must be assessed, as it repre-
sents a medical emergency. Similar to cognitive impairment 
in the primary care setting, delirium is common in the ED 
and yet may not be the focus of the emergency physician’s 
primary reason for attending to the patient and therefore 
not directly addressed (Elie et al., 2000; Hustey & Meldon, 
2002; Lewis, Miller, Morley, Nork, & Lasater, 1995). 
This is further complicated by the inability of ED physi-
cians to admit a patient with the diagnosis of delirium or 
“altered mental status” as these conditions are caused by 
other underlying medical emergencies. The recognition of 
delirium specifically and cognitive impairment in general in 
older ED patients is important given its prevalence (Hustey 
& Meldon, 2002; Wilber, 2006) and because it may be the 
principal symptom of a serious acute medical condition, 
impacting the clinical evaluation, patients’ understanding 
of medical information, and compliance with discharge 
instructions (Gerson, Counsell, Fontanarosa, & Smucker, 
1994). Guidelines to implement geriatric-friendly pro-
cesses of care in EDs recommend a two-step process for 
identifying delirium – a highly sensitive initial Delirium 
Triage Screen (DTS) followed by the use of a highly spe-
cific Brief Confusion Assessment (b-CAM) tool, conducted 
by a member of the medical team (e.g., nurse). A more in 
depth confirmatory assessment of potential delirium is then 
completed by another clinician (e.g, emergency physician, 
neurologist, neuropsychologist) for those screened posi-
tive at triage screen. However it is realized that not all EDs 
have the additional resources to support this level of assess-
ment of the older patient (Geriatric emergency department 
guidelines, 2014; Han et  al., 2013). Summit participants 
fully supported the need to recognize delirium as well as 
cognitive impairment and discussed the benefits of having 
an interdisciplinary team focused on geriatric care avail-
able. For example, systematic reviews indicate that adding 
a nurse practitioner specialist improves care (Ament et al., 
2015; Burl, Bonner, Rao, & Khan, 1998) as well as a care 
manager who can convey critical information to the next 
provider and access a referral network of services if indi-
cated. It was also acknowledged however, that consider-
ation should be taken with the implications of ED clinicians 
introducing the diagnosing of dementia (chronic cognitive 
impairment) in older patients for whom they do not have 
an established doctor–patient relationship. Delivery of 
such diagnoses to patients and their caregivers, in a set-
ting where the opportunity for interactive communication 
is often limited and would not allow for time to discuss the 
condition and its long-term management.
Consistent with recommendation above, the American 
Academy of Neurology has recommended that neurology 
be consulted in the ED and hospital for “high risk” cases in 
order to assess cognitive impairment using a delirium risk 
factor screening and preventive protocol (Josephson et al., 
2017). The definition of “high risk” individuals for that 
measure includes both predisposing and precipitating fac-
tors defined as one or more of the following: age 65 years 
or older, known major/mild neurocognitive impairment, 
current hip fracture, severe illness (a clinical condition that 
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is deteriorating or is at risk of deterioration), history of 
hypertension and/or alcoholism.
Current Trends: A Managed Care Perspective
In the changing landscape of medical care reimbursement, 
there are several trends relevant to understanding how cog-
nitive impairment assessment might be integrated in a man-
aged care setting.
Many trends in managed care could be adapted to the 
care of cognitive impairment. Managed care is moving 
away from pay for volume to pay for value, and is evaluat-
ing providers and making these data available to provid-
ers and patients. Consequently, use of a cognitive screen 
to identify “at risk” individuals can be monitored and 
reported out as a component of a necessary health report.
Furthermore, much can be learned by viewing collab-
orative care service models, such as the CMS Psychiatric 
Collaborative Care Services Model (COCM https://
www.cms.gov/Outreach-and-Education/Medicare-
Learning-Network-MLN/MLNProducts/Downloads/
BehavioralHealthIntegration.pdf). In this model, an 
enhanced rate is billed on a CPT code and the billing prac-
titioner shares the fee with the rest of the team, which can 
include a behavioral health care manager, psychologist, or 
psychiatric consultant. Incorporating a multi-stage model 
in which positive results from either a performance screen 
or an informant-based assessment is followed up by spe-
cialists (e.g., neurologist or neuropsychologist) can be of 
great value (Galvin, 2018; Rosenbloom et al. 2016). In a 
recent study by Grober and colleagues (2016) a two-step 
cognitive screening approach using a brief battery of neu-
ropsychological tests followed by a more extensive bat-
tery of neuropsychological tests when the initial battery 
indicated impairment was highly beneficial in identifying 
primary care patients with early dementia. Using a two-
step approach coupled with a care manager in the clinical 
setting could potentially lead to even greater incremental 
cost-effectiveness.
Also in the pay-for-value models, providers may earn 
increased reimbursement or other benefits such as market-
ing support through improved clinician metrics (such as 
improved quality measured through wellness assessments, 
or reduced average cost per episode) or facility metrics 
(such as reduced readmission rate, or reduced average 
length of stay). Performance measures generally focus on 
three aims: improving health quality outcomes, improv-
ing overall population health, and reducing healthcare 
costs (Berwick, Nolan, & Whittington, 2008). A  fourth 
aim, improving patient satisfaction, is highlighted in the 
Affordable Care Act, is sometimes included but is not 
always appropriate (Patient Protection and Affordable 
Care Act, 42 USC sec 1395ww 2015). For example, 
patient satisfaction may be difficult to measure for a pro-
vider whose work frequently involves communicating 
diagnoses with poor prognosis.
To assist providers, Optum Health developed an online 
tool (ALERT) to provide real-time feedback regarding 
clinical and claims data to identify outlier cases that may 
require increased interventions in order to avoid unneces-
sary medical interventions. The Summit participants 
promoted the notion that use of a standardized neuro-
psychological assessment instrument as part of a wellness 
assessment could potentially be adapted to assessment 
of cognition. To effectively use a tool such as ALERT for 
cognitive impairment, an appropriate metric will need to 
be identified, which can then be leveraged to demonstrate 
the utility of cognition assessment within the triple aim of 
improving population health, increasing patient satisfac-
tion, and reducing per-capita health care spending.
Additionally, the Summit participants recognized that 
while it is important for health care systems to assess cogni-
tion in order to improve quality care and reduce expenses, it 
is also important to encourage patient and caregivers of the 
need for assessment through education. Consequently for 
cognitive impairment, this may include educating patients 
and caregivers about the benefit of early detection to avoid 
use of inappropriate medications and improve care of med-
ical conditions and early diagnosis of the cause of cogni-
tive impairment so a care plan can be established. Summit 
participants also discussed creative approaches to encour-
age people to seek screening, such as cognitive impairment 
literature that could be sent to consumers explaining the 
process and benefits of being screened. Primary care pro-
viders will also need to be educated regarding the value 
of assessment. In the experience of Optum Health, adding 
even a 30-second application to every PCP visit elicited 
pushback; thus, including screening for cognitive impair-
ment would require education and payment incentives to 
encourage clinicians and medical systems to provide cogni-
tive assessment.
Using the Electronic Health Record in 
Assessment of Geriatric Patient Populations
The electronic health record (EHR) in general (also referred 
to as the CHR or Comprehensive Health Record) presents 
several potential roles in population health approaches, 
such as screening for cognitive impairment. Currently, the 
federal government requires that a minimum of 56 catego-
ries of data are shared between EHR platforms. This allows 
records to travel with the patient, improving the capacity 
to track changes in health parameters such as cognitive 
impairment over time. The EHR also allows the patient and 
all the clinicians involved in a patient’s care to access med-
ical information in one place, increasing the opportunities 
for coordination of interdisciplinary care.
The EHR can empower patients to see their test results, 
find discharge and follow-up instructions, post questions 
to their care providers, and schedule reminders for medi-
cation. Dr. Alban from Epic indicated that patients access 
their EHR seven times more frequently than care providers, 
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and that the largest group accessing EHRs are 50- to 
60-year-olds.
The EHR can incorporate hundreds of variables, col-
lecting social or other information in addition to medical 
information. In addition, many tools can be built into the 
CHR that would be relevant to screening for cognitive 
impairment, such as the ability to conduct remote video 
visits from within a linked application, or the addition of 
risk assessment tools that assess variables from the EHR 
and make recommendations about screening or further 
evaluation. Summit participants agreed that there needs to 
be standardized assessment tools and treatment plans that 
can be used across patient groups built into the EHR that 
allow for clear clinical pathways including when it is rec-
ommended to refer out to a cognitive specialist.
Psychometric Challenges Associated with 
Assessing Cognition in Older Adults
One size does not fit all with respect to tests and tools 
used to assess cognition. The “best” assessment method 
will depend on what is being assessed and why, and any 
assessment method must be appropriately validated and 
results compared to an appropriate normative standard for 
the population being assessed. Results can vary substan-
tially among different groups depending on age, education, 
intelligence, and social factors, making a single test with 
an absolute cutoff that could be applied to the entire adult 
population a challenging proposition. Psychometric con-
siderations for selecting an assessment method include test 
reliability and validity, identification of correct normative 
reference values, test accuracy, and method of test delivery 
(such as computerized vs. face-to-face testing).
Assessing cognitive impairment on the surface may 
appear to be straightforward, but given that cognitive 
impairment ranges from mild cognitive diminishment to 
profound cognitive impairment, detection can widely vary. 
The most subtle of these conditions, MCI, may or may not 
be detected by others, particularly if the patient is excep-
tionally verbal. However, MCI does have adverse effects 
on cognitive function and should be reliably detectable by 
neuropsychological tests. The DSM-5 defines two types of 
impairment, mild neurocognitive disorder (which corre-
sponds to MCI) and major neurocognitive disorder (which 
corresponds to dementia). These are defined as measured 
impairment in at least one cognitive domain, with perform-
ance in the 3rd–16th percentile placing a patient in the mild 
category and at or below the 3rd percentile in the major 
category. A recent analysis found a high false-positive rate 
in assessing for MCI, with almost 50% of the adults stud-
ied meeting criteria for mild neurocognitive disorder as 
defined in the DSM-5 (Holdnack et al., 2017). In another 
study, using the rigorous neuropsychological battery (NAB) 
assessment, over 1/3 of healthy adults would be classified 
as having mild neurocognitive disorder (Binder, Iverson, & 
Brooks, 2009; Iverson et  al., 2008). Another study found 
28% of people over age 75 met the criteria for MCI using 
only neuropsychological criteria that included low per-
formance in at least two of ten tests, and in comparing 
two approaches to detect MCI, found discordant results in 
almost 37% of cases (Saxton et  al., 2009). These studies 
highlight the importance of choice of assessment method 
and of test interpretation. Interpretation algorithms should 
be optimized to meet the objectives of the assessment, and 
may need to be adjusted based on whether the false-positive 
(a test result that incorrectly indicates cognitive impair-
ment) or false-negative (a test result that incorrectly indi-
cates the absence of cognitive impairment) rate should be 
minimized so that selection criteria serves as an improve-
ment over subjective complaints and clinical judgment (see 
Edmonds et al., 2014, 2015, 2016). It is important to keep 
in mind that identifying precise criteria is difficult because 
the performance of healthy and clinical groups will overlap.
To obtain valid data, tests must be delivered in a per-
son’s primary language, and must be normalized within 
a representative population and results compared to an 
appropriate baseline. The participants recognized the over-
looked fact that according to the Census Bureau from the 
2013 American Community Survey (ACS), 61.8 million 
Americans do not speak English at home (https://www.
census.gov/acs/www/data/data-tables-and-tools/). Because 
cutoffs for identifying impaired performance will be 
defined relative to normative reference values it is essen-
tial to have an accurate measure of the distribution for a 
given population. Normative results can vary depending on 
reading ability, occupation, language and culture. Summit 
participants also emphasized the fact that many additional 
factors affect the results of a cognitive assessment including 
pain, lack of sleep, fatigue, stress, anxiety, and depression, 
all of which must be considered when interpreting results.
Another consideration that must be acknowledged 
is that not all cognitive impairment is permanent and 
impaired cognitive performance frequently returns to nor-
mal over time (Brooks, Iverson, Holdnack, & Feldman, 
2008). Thus, future algorithms need to become more 
sophisticated and adjust criteria for impairment depend-
ent upon specific patient characteristics (Brooks, Iverson, 
Feldman, & Holdnack, 2009).
While the summit participants were fully supportive of 
the need for cognitive screening, the consensus was that a 
cognitive screening program must consider time and cost, 
the training and expertise required of those administering 
the screening, the sensitivity and specificity of the screening 
method, and how or whether to monitor change in cogni-
tion over time. The group recognized the potential for com-
puterized testing which presents several advantages such 
as ease of use, standardization, and the potential for auto-
mated scoring and interpretation, though results can depend 
on computer literacy (Iverson, Brooks, Ashton, Johnson, & 
Gualtieri, 2009). The group however also recognized the 
need to consider the assessment from the perspective of the 
patient who may be computer-adverse or find the hospital 
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room ED setting too distracting. In those cases, paper and 
pencil testing or at-home evaluations may be preferable.
Breakout Groups
Following the presentations and discussions, the summit 
attendees broke into four focused groups to discuss the fol-
lowing topics:
 • The implementation of screening protocols in primary 
care and emergency department settings
 • Identification of “at risk” patients: the role of registries 
and what occurs when a person tests positive on a screen
 • Compensation for services – moving from fee-for-service 
to full risk and value-based payment models
 • Next steps: creating clinical pathways for persons iden-
tified as potentially having a cognitive disorder
Further key takeaways from each group are described below.
The Implementation of Screening Protocols 
in Primary Care and Emergency Department 
Settings
The Summit group determined that an effective cognitive 
screening protocol will need to differ based on clinical setting. 
The group acknowledged that cognitive impairment in the ED 
typically falls into two important and ED-specific categories: 
chronic, i.e. a likely dementing disorder, which impacts the 
care that patient receives by influencing ability to gather an 
accurate history and perform an informative physical exam 
and the person’s ability to understand and participate in pro-
cesses of care and discharge planning; and acute, i.e. delirium, 
which is an essential ED presentation since it usually repre-
sents a symptom of an acute occasionally life-threatening 
medical condition. Strategies for identifying them are signifi-
cantly different in the ED, however use of an initial and quick 
screening measure (preferably completed within one minute) 
could include an initial triage determination followed by an 
alternative screen in cases where delirium is suspected. Stress, 
pain, and other factors frequently present in ED patients and 
can affect performance on cognitive screens; thus, alternative 
factors must be considered when assessing cognitive impair-
ment in the ED. In the primary care setting, a test may be able 
to take as long as 5min and should be considered as part of 
the AWV or any visit when there is a suspicion of memory 
concern. In the primary care setting, novel approaches such 
as treating cognitive screening as a laboratory test (performed 
outside of the PCP office) may present an alternative to find-
ing time to conduct screening during an office visit.
In both settings, screening may be made more efficient 
by incorporating information about demographic and 
medical risk factors from the patient’s EHR. A two-tiered 
approach could be considered in which initial demographic 
and medical risk factors apparent in the EHR are factored 
in to the algorithm to identify those with at high risk for 
cognitive impairment (Walters et al., 2016). Once high-risk 
candidates are identified, they can be referred to a cognitive 
specialist (neurologist geriatrician, geriatric psychiatrist, or 
neuropsychologist). Collateral information from inform-
ants also should be considered when available.
Risk factors that might identify high-risk patients to 
guide cognitive screening in the primary care and ED set-
tings include age, history of stroke, educational attainment 
less than 12 years, depressive symptoms, presence of diabetes 
mellitus, substance abuse, and caregiver assistance needed 
for finances and/or medication (The Gerontological Society 
of America Workgroup on Cognitive Impairment and 
Earlier Diagnosis: Report and Recommendations, 2015). 
Other neurological diseases, such as a history of traumatic 
brain injury, multiple sclerosis, epilepsy, and Parkinson’s 
disease are at high risk of cognitive impairment and could 
be included. Additional less-obvious factors that were iden-
tified included medication non-adherence, frequent calls 
to the PCP office, and after visit summary confusion. The 
summit participants also recommended future research to 
identify the optimal risk factors that could identify high-risk 
individuals and can be obtained from data in the EHR.
Also, in both the ED and primary care setting, a care 
pathway should be readily available that identifies clear next 
steps after positive findings. It may be inappropriate to rely 
on a single positive cognitive screen for dementia especially if 
performed in a less-than-ideal setting, the ED. A strategy sim-
ilar to that followed for identifying hypertension might be 
followed. A diagnosis of hypertension requires a high blood 
pressure reading on at least two visits. A  separate visit to 
verify cognitive impairment with either another test instru-
ment (for example the more extensive 30-point, 10–15min 
Montreal Cognitive Assessment) or an alternative version of 
the same screening instrument would also allow a clinical 
discussion and interpretation before initiating a full cognitive 
evaluation. Summit participants recognized that to encour-
age screen usage it would be helpful to have more evidence 
that screening improves patient outcomes (such as reducing 
return visits to the ED or improving treatment adherence 
and care follow-up). In both settings, the care team should 
understand the benefit behind why the screen is being done.
In all cases, the patient should be screened in their pre-
ferred language. If this is not possible, a risk factor-based 
algorithm may be preferred to administering a screening 
test without language concordance because language dis-
cordance will likely lead to false positive results. Language 
concordance has been demonstrated to improve outcomes, 
decrease medical errors, improve treatment compliance, 
and decrease costs (Fernandez et al., 2011; Jih et al., 2015; 
Meuter et al., 2015; National Standards for Culturally and 
Linguistically Appropriate Services in Health Care, 2001; 
Parker et al., 2017; Tang et al., 2011). The summit group 
recommended that hospital systems identify the top five 
languages used by their population and prepare for screen-
ing within these languages. This will involve identifying 
linguistic assets and implementing appropriate staffing, 
instrumentation, and care pathways.
Additionally, the group recommended that screening 
tests be shown to be reliable and validated in different 
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target populations, considering cultural factors in addition 
to language factors (Ardila, 2005; De Jesus-Zayas, Buigas, 
& Denney, 2012; Romero et al., 2009).
A screening test for cognitive impairment should be able 
to be administered by any trained member of healthcare 
team. Some levels of screening, such as The Eight-Item 
Informant Interview to Differentiate Aging and Dementia 
(AD8 dementia screening interview), or collecting written 
information from the patient, could be performed by medi-
cal technicians and office staff. With proper training, medi-
cal technicians could complete other screening assessments.
The group recommended that the screening be charac-
terized as a measure of brain health since screening tests 
are not diagnostic. It was also emphasized that having a 
geriatric trained behavioral health worker, or case manager 
(or a repurposed member of the existing team) to walk the 
patient through the screening and subsequent follow-up 
could reduce recidivism and decrease utilization. This will 
be increasingly important as compensation moves to full 
risk reimbursement models. Identifying an advanced, tech-
nologically effective but least-cost method of screening and 
follow-up should be a priority area of behavioral work-
force policy (Garety et  al., 2018; Nemec & Chan, 2017; 
Raney, Bergman, Torous, & Hasselberg, 2017).
The group stressed that the results of cognitive screen-
ing results should always be integrated into the EHR in a 
manner that allows data to be captured for quality metrics, 
population health management, syndrome surveillance, and 
research. The EHR may also be capable of scoring screening 
tests and offering suggested interpretation, optimizing cli-
nician time. Screening result interpretation should be avail-
able to all of a patient’s providers because as a dominant 
comorbidity cognitive impairment influences the manage-
ment and choice of drug treatment for all other conditions. 
This can be accomplished by utilizing EHR problem lists 
to identify cognitive impairment, health maintenance tools 
and alerts, and condition registries. The group recom-
mended that EHRs create modules that include confusion 
and cognitive impairment screens so that hospital systems 
do not have to individually create such tools.
Identification of “At Risk” Patients: The Role of 
Registries and What Occurs When a Person Tests 
Positive on a Screen
The objective of screening for cognitive impairment is to 
improve patient care and outcomes for people with cog-
nitive difficulties. The group emphasized that screening is 
not diagnostic; it provides important information to the 
clinician to make informed decisions and to consider next 
step pathways. Ultimately the goal of screening is to lead 
to improved patient care. In turn, screening combined with 
additional sources of information can lead to identifying 
remediable causes of cognitive impairment that can be med-
ically addressed; transition planning that can better ensure 
patient safety and adherence to recommended treatment 
or follow up care; reduction in hospital, PCP, and ED use; 
and finally provide education, planning, and support to the 
patient and family/caregiver to improve quality of life.
Identifying “at risk” patients differs depending on the 
medical setting. In the ED the primary goal may be to iden-
tify risk to prevent, recognize, and treat delirium. In this set-
ting, the patient may be best assessed by a primary ED nurse 
and if delirium is identified, a pathway including evaluating 
underlying causes and deploying a care plan can be pursued. 
If there is a history of cognitive impairment or cognitive 
complaints, a delirium prevention protocol can be imple-
mented (Josephson et al. 2017; Marcantonio, 2017). In the 
primary care setting, the primary goal may be to optimize 
adherence to personalized care plans. Assessment may occur 
during the AWV or next care visit based on risk factors or 
response to brief targeted questions. Positive screening 
results would lead to a pathway involving further assess-
ment and additional support. While some patients may not 
want to be told that they require a workup for cognitive 
impairment and a referral to a cognitive specialist such as 
neurologist, studies have shown that patients experiencing 
cognitive problems favor being told that they have a cog-
nitive impairment and the possible cause of their problems 
(Elson, 2006).
A knowledge gap identified by the Summit group is what 
information to leverage from the EHR/CHR to identify at 
risk patients in the primary care and ED settings. Registries 
comprised of databases may be used to fill this gap. The 
group however provided some cautionary thoughts about 
this approach and the ethics of identifying and classifying 
patients as “at risk” without their knowledge.
The group agreed that the benefits of data-driven algo-
rithms to identify people at risk for cognitive impairment 
outweighed the potential unintended consequences. The 
EHR can assist in this process by ensuring that all older 
adult patients, whether a member of an ACO or not, are 
evaluated on an annual basis. The resulting cognitive 
screening data can then be added to other medical and non-
medical, non-cognitive information such as, the presence of 
diabetes, medications that impact cognition, age, reason for 
visit, and the number of phone calls or messages to clini-
cians, as well as psychological, functional, and social areas. 
Once collected the data can then be used to build an algo-
rithm to stratify patients on the basis of risk for cognitive 
decline. Additional patients would be screened based on 
complaint of a change in cognition reported by the patient 
or family member. Use of the EHR in this fashion can also 
minimize the implicit bias that can be present in the pri-
mary care setting which affects the rates at which different 
patients are referred to specialist for follow up.
The summit group agreed that once an algorithm is empir-
ically determined it should be reexamined to ensure that it 
is providing a valid procedure at each location or whether 
geographic distinctions need to be accounted for. The group 
asserted that ideally there needs to be a care pathway to dir-
ect follow up after screening, including clear guidelines on 
how often follow up assessments need to be conducted based 
upon a screening result in combination with other factors. 
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Furthermore, health systems should aspire to include some 
type of care team follow-up or contact via phone call.
Compensation for Services – Moving from 
Fee-for-Service to Full Risk and Value Based 
Payment Models
This group emphasized that screening is different from assess-
ment or diagnosis. Screening as part of a collaborative care 
pathway fits well into multispecialty, longitudinal episodes of 
care models and bundled payment models. However, the care 
team should include non-physician clinicians not eligible for 
Medicare reimbursement for this service (e.g., psychologists) 
because they have expertise in cognitive assessments. These 
care and payment models that bundle services over longitu-
dinal episodes or that are delivered by a team of professionals 
may deliver improved health outcomes for dementia patients 
and their caregivers, but require further study.
Presently insurance companies are contending with bot-
tlenecks to care, as demand increases while simultaneously 
access to care decreases. Incentives for the system to evalu-
ate more patients could incorporate care pathways and 
opportunities for physician “extenders” to provide care to 
reduce physician burden and facilitate care across settings. 
For cognitive screening, this could involve offering higher 
reimbursement for initial evaluations for at-risk individu-
als, and additional payments for practices furnishing higher 
levels of care. Telehealth services might also be leveraged 
to reduce caregiver burdens, especially when delivering care 
to patients living in rural or isolated settings, or when lan-
guage concordance is of issue. Early detection or diagnosis 
has the potential for cost saving and redirection of resources 
to those with the most pressing health related problems. 
This possibility deserves further study. Alberdi, Aztiria, and 
Basarab (2016) have recently addressed this as a cost saving 
issue with respect to the early diagnosis of Alzheimer’s dis-
ease. As for dementia, in a letter to the editor discussing the 
benefits of early diagnosis, the editor of the International 
Journal of Geriatric Psychiatry asserts that “…interven-
tions can take place to avoid crises” and “[the] economic 
benefit–avoiding unnecessary admissions and institutional-
ization–is well known” (Burns, 2012, e3556). If “planning” 
has the positive attributes suggested for most future activi-
ties it would appear that early detection of dementia would 
clearly help avoid excessive and unnecessary costs.
Next Steps: Creating Clinical Pathways for 
Persons Identified as Potentially Having a 
Cognitive Disorder
The final group noted that designing clinical pathways 
assumes the correct population was screened using a valid 
and accurate test. As stated above, reasons for potential 
false positives should always be included in the interpret-
ation of results and considered before proceeding.
Immediate next steps will depend on the clinical set-
ting and the severity of the screening result. In the ED, an 
established clinical care pathway should be implemented for 
delirium prevention and delirium treatment that includes 
a strategy for assessing potential causes as well as for the 
management of the condition. In this regard the pathway 
could include determining acute care needs and the need for 
admission but also remind providers to establish surrogate 
decision makers, and to consult with a cognitive specialist on 
the team. When a screen for cognitive impairment is positive 
but delirium is not present, the care pathway would include 
obtaining information from available sources such as collat-
eral informants. A care manager or social worker might be 
activated to direct the patient to appropriate resources and 
help ensure compliance with follow-up plans.
In the ED, positive screen results affect clinical decision 
making in the design or modification of care plans taking 
into account the patient’s capacity for decision making or 
understanding, assessment of safety for discharge, identifica-
tion of discharge considerations such as who will be help-
ing to care for a patient, providing written information to 
the patient and family/caregiver and referrals to appropriate 
resources, and increasing follow up. A positive screen may 
also trigger assessment by an interdisciplinary team, referral 
to follow-up for cognitive disorder or dementia, or referral 
to outpatient treatment if behavioral issues are predominant. 
Assessment via an interdisciplinary team, including social 
work and clinical care managers, may also generate referrals 
to home and community-based services and social supports.
In the primary care setting, a positive screening result 
would result in implantation of a care plan in line with exist-
ing guidelines from sources such as the AGS and Alzheimer’s 
Association or specific to the healthcare system. The plan 
should include confirming cognitive impairment on a second 
visit, identifying and treating remediable causes of cognitive 
impairment, and determining a specific protocol for how 
cognition would continue to be monitored over time, and 
when a referral to a specialist is indicated. Specialist refer-
rals may be triggered by atypical presentations and behav-
ioral dysregulation and would rely on recommendations 
from existing guidelines. Specialist referrals also would be 
appropriate if performance and interpretation of a cognitive 
evaluation to determine the cause of impairment is outside 
the provider’s scope of practice. Specialists such as neurolo-
gists, geriatric psychiatrists, geriatricians, and neuropsychol-
ogists can be called on to clarify diagnosis, conduct further 
testing to inform treatment and track response to treatment, 
and to address emotional distress and environmental adjust-
ment, provide education, and caregiver support. Specialist 
availability will depend on available resources, so any care 
plan must provide flexibility for settings with no access to 
certain specialists. This group emphasized the value for 
patients with cognitive impairment of care managers who 
can organize care, provide educational information and 
materials, direct patients to community resources and other 
social supports, and address functional needs that can min-
imize risks of decline.
Many types of educational materials can be provided to 
patients and their families and caregivers. The information 
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should be adapted as needed for patient and caregiver. 
Helpful materials may include:
 • Condition-specific information (e.g., symptoms, expected 
progression, etc.)
 • Caregiver resources and support (includes respite and 
social support)
 • Community Resources (e.g., adult day health, commu-
nity/senior centers, adaptive sports programs, paratran-
sit services, Neuro Recovery centers, etc.)
 • How to manage functional limitations, supervision 
needs, and behavioral changes
 • Safety Issues within home and community
 • Advance Care Planning (e.g., POA, Living will, 
Guardianship)
 • Referral to existing information sources (e.g., Alzheimer’s 
Assoc., Council on Aging, AARP, etc.)
 • Empirically validated options to promote positive cog-
nitive health (e.g., exercise, social and community 
involvement, healthy diet, cognitively stimulating activi-
ties, etc.)
 • Information about sleep – importance of healthy sleep 
patterns and risks for cognition related to disrupted 
sleep
Table 2. Key takeaway conclusions
•  There is a need to educate the public regarding the difference between screening, which identifies individuals at risk within an 
asymptomatic population, and diagnosis of a specific condition such as delirium or a dementing disease.
•  It is important to emphasize that cognitive impairment screening is a measure of brain health, which needs to be monitored regularly in 
at-risk individuals to determine the fidelity of brain functioning.
•  Cognitive impairment in older adults has multiple possible causes, including medical and psychiatric conditions, such as endocrine and 
metabolic conditions, chronic pain, depression, sleep disturbance, medication side-effects, delirium, and brain diseases causing dementia, 
with Alzheimer’s disease and MCI being the most common.
•  Cognitive impairment is a clinically dominant comorbidity. Cognitive impairment is so serious that it overshadows the management of 
other health problems. It influences the effectiveness of doctor–patient communication, treatment adherence, the likelihood of medical 
follow-up, the selection of appropriate medications, and likely medication side effects.
•  Cognitive evaluation to determine the causes and remediable factors contributing to impairment is necessary to guide appropriate choice 
of medications and management.
•  Collaborative care models that include the expertise of specialists in the area of cognitive assessment (i.e., neuropsychologists, neurologists 
and geropsychiatrist) may be cost-effective and provide better quality care. In the emerging value over volume payment models, inclusion 
of cognitive specialists fits well into new team-based payment models that emphasize overall wellness.
•  The EHR presents a great deal of promise for risk stratification modeling and for monitoring changes in cognitive screen performance 
over time. EHR automated tools for assessing and recording the results of individual’s cognition over time need to be developed.
•  There is a need to increase awareness of identifying risk factors beyond medical data that include social, behavioral, and functional 
information.
•  No one size fits all when assessing for cognitive impairment. It is important to recognize that the goals and means of cognitive assessment 
depend on the clinical setting and differ between the ED and the primary care environment.
•  There is an important role that care managers or coordinators play in ensuring that people stay on a care pathway, and may also increase 
patient and caregiver satisfaction.
•  There are deficiencies in health services in rural and economically disadvantaged America, resulting in a large gap in access to care and 
differences in resources such as care coordinators and cognitive specialists.
• Assessment of cognition must be done in a linguistically and culturally appropriate way to obtain meaningful results.
•  There is a great need to increase advocacy regarding Medicare coverage and payment for a range of services and supports for beneficiaries 
with cognitive impairment (for example, including reimbursement for psychologists on interdisciplinary teams).
Table 3. Identified knowledge gaps
•  The need for research to determine whether “best practice” algorithms will guide risk stratification models and improve detection of 
cognitive impairment.
•  Empirical determination of the best screening tools to use to assess cognitive impairment when taking in to consideration patient and 
provider acceptability, cost, time, sensitivity and specificity.
•  How best to factor in language and cultural determinants when screening for cognitive impairment.
• How best to factor in a person’s age, intelligence, and education when interpreting screening and assessment results.
•  What care models are most effective, time and cost efficient when conducting cognitive screening in the absence of clinical signs of 
cognitive disorder.
• How to consider repeated screening and the use of baseline data against which future assessments can be compared.
•  What ways the EHR can best be leveraged to identify at risk individuals and document for all providers the cognitive health status of their 
patients.
• How best to utilize “smart technologies” and how to integrate these technologies with traditional medical data.
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Key Takeaways and Knowledge Gaps
In conclusion, the Summit attendees emphasized the power 
of an interdisciplinary approach to improve care and the 
significant range of expertise available when professional 
organizations come together. To summarize, the key take-
away conclusions are listed in Table 2.
Furthermore, the Summit participants identified knowledge 
gaps that exist which can be the basis for future collabora-
tive research endeavors (see Table 3).
For economists, an increase in the number of options or 
an expansion of the data set often provides a basis for a 
more efficient and quite possibly a lower cost solution to 
accomplishing an objective. Even where a final resolve is 
not available, early detection at least could improve the 
prospects for better quality of life associated with a cog-
nitive impairment diagnosis. With respect to Alzheimer’s 
disease, Barnett and colleagues (2014) studied early 
identification of cognitive loss within a cost-effective-
ness context and found that net economic benefits were 
reduced by approximately 17% for every year of delayed 
identification.
Finally, the Summit participants suggested follow up 
meetings to track success in the assessment of cognitive 
disorders among the aging population. The participants 
expressed hope that the proceedings from this meeting will 
provide practitioners and health systems with useful guide-
lines to consider when developing clinical practice path-
ways. Given the complexity of clinical decision-making, 
diversity of services required, and the need for coordination 
of services for the person experiencing cognitive impair-
ment, implementation of a team-based, collaborative care 
approach may best serve to improve the identification and 
care of people with cognitive disorders.
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